RecruitingPhase 1Phase 2NCT06530849

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

A Phase 1/2 Clinical Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Sponsor

Gracell Biotechnologies (Shanghai) Co., Ltd.

Enrollment

118 participants

Start Date

Aug 22, 2024

Study Type

INTERVENTIONAL

Conditions

Refractory Systemic Lupus Erythematosus

Summary

This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GC012F Injection for people with refractory systemic lupus erythematosus. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGC012F Injection

GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19

Locations(2)

Research Site

Shanghai, China

Research Site

Wuhan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06530849

Related Trials

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

NCT066766311 location